Career Strategy
Building a U.S. Career as a Polish biotech CEO — August 2023
Everything you need to know about the latest changes and how they affect your O-1 strategy.
The O-1A visa as the primary pathway for biotech executives
The O-1A visa is the primary immigration option for biotech executives who have achieved recognition placing them at the upper tier of their field. For a Polish biotech CEO, the central analytical question is not whether the individual is accomplished—most senior biotech executives are—but whether the evidence can demonstrate extraordinary ability within the meaning of 8 C.F.R. § 214.2(o)(3)(ii). The standard requires satisfying at least three of the eight regulatory criteria, or demonstrating through the totality of evidence that extraordinary ability exists even where specific thresholds are approached rather than clearly exceeded.
Polish biotech professionals often have academic records and publication histories that form a strong foundation for O-1A petitions. Many pursued doctoral training in Poland or elsewhere in Europe before moving into industry, and their academic work may satisfy the original contributions or published material criteria if it has been cited, adopted, or recognized by the broader scientific community. The question is whether the transition from academic researcher to executive has continued to generate independently documented scientific recognition, or whether recent years have been primarily operational without producing evidence that maps clearly onto the regulatory criteria.
Building a U.S. biotech career as a Polish national involves navigating the practical realities of O-1A sponsorship. The visa requires a U.S.-based petitioner—either a U.S. employer or an agent maintaining a roster of specific engagements. For Polish executives seeking to enter the U.S. market rather than transition from an existing U.S. position, agent petitioners are common, though the agent must document the specific consulting arrangements through a detailed itinerary and supporting contracts or letters of intent. The choice of petitioner structure affects the flexibility of the visa and the nature of authorized work activities.
Publications, scholarly output, and the peer recognition record
The published material criterion under the O-1A regulations covers authored scholarly publications appearing in professional journals or other professional media. For a biotech CEO who came up through academic research, this criterion is often naturally satisfied: doctoral research, postdoctoral work, and early-career industry contributions typically generate peer-reviewed publications in journals such as Nature Biotechnology, Cell, PNAS, the Journal of Clinical Investigation, or comparable venues. Documentation requires evidence that the publications are peer-reviewed and that the journals have standing in the field, typically established through impact factor data and editorial board information.
The citation record is central to demonstrating that published work has had measurable impact. Citation counts from Google Scholar, Web of Science, or Scopus—combined with expert letters from independent researchers who explain the significance of specific publications—provide the strongest foundation for the criterion. Adjudicators are not expected to evaluate scientific content independently; they rely on documentation to understand whether publications represent contributions engaged with by the scientific community. An expert letter identifying which papers have been influential and why—citing specific adoption of methods, extension of findings, or changes in research practice—is far more persuasive than a letter offering general praise without specifics.
For Polish biotech executives who have been primarily operational in recent years and whose publication record is several years old, the original contributions criterion may be more current and relevant. Contributions to proprietary drug development, novel therapeutic approaches, or technology platform development may qualify as original contributions of major significance if recognized in the broader biotech community—through patent records, licensing agreements, coverage in industry publications such as STAT News or FierceBiotech, or through expert testimony from recognized scientific advisors who can assess the contribution's significance relative to competing approaches in the field.
Original contributions and the major significance standard
The original contributions criterion under 8 C.F.R. § 214.2(o)(3)(ii)(A)(4) requires contributions of major significance to the field. For biotech executives, the most common contributions asserted are drug discovery programs that led to clinical development, technology platforms adopted by others in the industry, and proprietary methods that have become standard practice. The regulatory standard does not require the contribution to be publicly available—unpublished proprietary work can satisfy the criterion—but it does require independent corroboration that the contribution is genuinely significant rather than merely technically competent.
Expert letters are the primary mechanism for establishing major significance. An effective letter does not simply describe what the contribution is; it specifically explains why it matters in context, what problem it solves that was not previously solved or not solved as effectively, and how others in the field have engaged with or responded to the contribution. For a CEO whose primary contribution is a clinical-stage drug program, a letter from an independent pharmacologist who can assess the therapeutic hypothesis and its significance relative to competing approaches is far more persuasive than a general endorsement from a business colleague without scientific specificity.
Patent records, licensing agreements, and transaction documentation supplement expert letters by providing objective evidence of commercial and scientific recognition. A patent cited by other patents is evidence that the innovation has been engaged with by others in the field. A licensing agreement with a major pharmaceutical company documents that independent parties with industry expertise valued the contribution enough to transact around it. An out-licensing deal, acquisition offer, or strategic collaboration agreement can demonstrate that independent technical reviewers assessed the contribution as significant. These commercial records are generally available for inclusion in a petition, provided that confidentiality obligations are addressed through redaction with appropriate explanation.
Judging and critical role criteria for senior executives
Senior biotech executives regularly participate in activities satisfying the judging criterion under 8 C.F.R. § 214.2(o)(3)(ii)(A)(2): serving on scientific advisory boards, reviewing grant applications for NIH or NSF, participating in peer review for journals, or evaluating pitch decks as an investor or advisor. Documentation requires evidence of the specific reviewing activity—invitation letters from the reviewing organization, confirmation emails from grant program officers, or editorial acknowledgment letters. For advisory board service, the board charter, meeting records, and a letter from the board chair explaining the selection criteria and the board's evaluative function are appropriate supporting materials.
The critical role criterion under 8 C.F.R. § 214.2(o)(3)(ii)(A)(5) is frequently satisfied for biotech CEOs who lead organizations with distinguished reputations in the industry. Documentation typically includes evidence of the organization's recognition: press coverage in major biotech publications, FDA Fast Track or Breakthrough Therapy designations, venture funding from recognized institutional investors, partnerships with major pharmaceutical companies, and industry awards. The organization's distinguished reputation must be documented independently of the CEO's own achievements—the argument is that the organization is recognized as distinguished and the CEO's role is the central leadership position driving the organization's mission.
For O-1A petitions relying on the critical role criterion, the description of the role itself must be specific and authoritative. The petition should describe the CEO's specific responsibilities, the direct operational impact of their decisions, and the degree to which the organization's scientific and commercial direction depends on their leadership. An organizational chart, board resolution, employment agreement, and a letter from a board member or major investor who can independently attest to the CEO's critical position can supplement the standard employer support letter. The distinction between a critical role and routine senior management lies in the specificity and authority with which the role is documented.
High salary evidence and compensation benchmarking
The high remuneration criterion under 8 C.F.R. § 214.2(o)(3)(ii)(A)(6) requires that the beneficiary commands a salary or other remuneration substantially above that paid to others in the field. For biotech CEOs, compensation typically includes base salary, equity grants, bonuses, and potentially venture carry or royalty payments, all of which can be considered as part of the total compensation picture. Benchmarking requires identifying appropriate peer data from biotech industry sources such as Radford, Korn Ferry, or Mercer, combined with SEC proxy disclosures for comparable public companies and venture compensation benchmarks for private companies at similar stages.
The comparison group must be carefully defined. A CEO of a Series A biotech startup should not be compared to CEOs of large-cap pharmaceutical companies; the comparison should be to executives at a similar stage, in a similar therapeutic area, and of similar company size. If the beneficiary's total compensation—including the fair market value of equity grants based on the most recent 409A valuation—substantially exceeds the median for the appropriate peer group, that comparison is strong evidence for the criterion. If the company is early-stage and cash compensation is modest, the equity component and implied total compensation at expected exit valuation can be part of the argument, supported by documentation and expert analysis.
For Polish nationals seeking to establish U.S. employment, demonstrating high remuneration may require documentation of compensation offered rather than compensation received. Offer letters, signed employment agreements, and equity grant documentation can establish the prospective compensation structure. An expert letter from a biotech compensation consultant who can analyze the offer package in the context of the applicable peer group provides an independent framework for evaluating whether the compensation is substantially above average. Documentation of prior compensation in Poland converted to USD at applicable exchange rates can also establish the historical compensation trajectory that supports the current compensation claim.
Assembling a complete O-1A petition strategy
Building a complete O-1A case for a Polish biotech CEO requires selecting three or more criteria from the eight regulatory options and assembling evidence that is current, specific, and independently corroborated. The strongest cases typically combine published material or original contributions—demonstrating scientific recognition—with judging or critical role criteria demonstrating professional authority, and high remuneration demonstrating that the field has valued the individual's expertise in financial terms. Supporting documentation from independent expert witnesses who know the beneficiary's work but are not employed by the petitioning organization is essential to establishing that the recognition claimed is genuine and not merely self-reported.
The I-129 petition package should include a comprehensive attorney brief that walks the adjudicator through each criterion in turn, explaining the regulatory standard, describing the evidence submitted, and connecting the evidence explicitly to the regulatory requirement. The brief should anticipate likely objections—particularly the argument that the beneficiary is accomplished but not extraordinary, or that the organization is not distinguished enough to satisfy the critical role criterion—and address those arguments with specific evidence and legal analysis. A well-structured petition brief reduces the likelihood of an RFE by pre-answering the questions an adjudicator would otherwise need to raise.
Polish nationals applying for O-1A visas follow the standard processing pathway: the I-129 is filed with USCIS, and if approved, the beneficiary applies for the visa at the U.S. Embassy in Warsaw or, if already in the U.S. in another status, through a change of status request. Premium processing under 8 C.F.R. § 103.7 is available for an expedited adjudication timeline and is advisable for professionals whose career timing is tied to specific commercial milestones, clinical timelines, or board-level commitments. The current premium processing fee and timeline should be confirmed at the time of filing, as USCIS adjusts these periodically through the Federal Register.